1. Home >
  2. M&A >
  3. Divestiture >
  4. Poland >
  5. Bio-Rad Acquires Curiosity Diagnostics

M&A Deal Summary

Bio-Rad Acquires Curiosity Diagnostics

On August 3, 2022, Bio-Rad acquired life science company Curiosity Diagnostics from Scope Fluidics for 170M USD

Acquisition Highlights
  • This is Bio-Rad’s 7th transaction in the Life Science sector.
  • This is Bio-Rad’s largest (disclosed) transaction.
  • This is Bio-Rad’s 1st transaction in Poland.

M&A Deal Summary
Date 2022-08-03
Target Curiosity Diagnostics
Sector Life Science
Buyer(s) Bio-Rad
Sellers(s) Scope Fluidics
Deal Type Divestiture
Deal Value 170M USD

Target

Curiosity Diagnostics

Warsaw, Poland
Curiosity Diagnostics is a late-stage, pre-commercial platform company, is in the process of developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market. Curiosity Diagnostics was founded in 2012 and is based in Warsaw, Poland.

Search 206,099 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bio-Rad

Hercules, California, United States
Category Company
Founded 1952
Sector Medical Products
Employees7,700
Revenue 2.6B USD (2024)
DESCRIPTION

Bio-Rad is a developer, manufacturer, and marketer of a broad range of medical tools and services to the life science research and clinical diagnostics markets. Bio-Rad was incorporated in 1952 and is based in Hercules, California.

DEAL STATS #
Overall 8 of 9
Sector: Life Science M&A 7 of 7
Type: Divestiture M&A Deals 2 of 2
Country: Poland M&A 1 of 1
Year: 2022 M&A 1 of 1
Size (of disclosed) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-04-09 Celsee

Ann Arbor, Michigan, United States

Celsee, Inc. offers instruments and consumables for the isolation, detection, and analysis of single cells. Celsee was founded in 2011 and is based in Ann Arbor, Michigan.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2025-02-13 Stilla

Villejuif, France

Stilla develops and markets next-generation digital PCR instruments, consumables, and assays. The company’s Nio® family of all-in-one droplet digital PCR systems aids the development of a wide range of genetic tests and molecular assays across multiple applications including liquid biopsy for oncology diagnostics, cell and gene therapy, organ transplant testing, infectious diseases, and food and environmental testing. Stilla was formed in 2013 and is headquartered in Villejuif, France.

Buy -

Seller(S) 1

SELLER

Scope Fluidics

Warsaw, Poland
Category Company
Sector Life Science
DESCRIPTION

Scope Fluidics is a developer of innovative technological solutions for the medical diagnostics and healthcare markets through wholly owned limited liability companies. Scope Fluidics is developing the PCR|ONE technology for rapid, automated detection of infections via highly multiplexed PCR assays, and the BacterOMIC system for high-content automated antibiotic susceptibility testing. Scope Fluidics is based in Warsaw, Poland.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
Country: Poland M&A 1 of 1
Year: 2022 M&A 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal